Compare American Water Works Company Inc (AWK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Novo Nordisk A/S — how do they compare? American Water Works Company Inc trades at $132.11 (market cap $25.69B), while Novo Nordisk A/S trades at $50.57 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 8.4× American Water Works Company Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| AWK | NVO | |
|---|---|---|
Market Cap | $25.69B | $214.94B |
Sector | Utilities | Health |
52-Week High | $147.00 | $71.70 |
52-Week Low | $121.13 | $35.29 |
Enterprise Value | $41.25B | $233.91B |
Dividend Yield | 2.72% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Water Works (AWK) trades at $131.53, up 0.64% with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth from $3.8B in 2022 to $5.14B in 2025, maintaining net margins above 21%. Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while the company continues infrastructure investments and community initiatives.
AWK presents a stable utility investment with moderate upside to the $137 consensus target. Key risks include regulatory approvals for rate increases and high capital expenditures. Analyst sentiment is balanced with 47% buy ratings, though recent earnings misses warrant caution ahead of Q2 2026 results on July 29, 2026.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
